GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » Capex-to-Operating-Income

LTR Pharma (ASX:LTP) Capex-to-Operating-Income : 0.00 (As of Jun. 2023)


View and export this data going back to 2023. Start your Free Trial

What is LTR Pharma Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

LTR Pharma's Capital Expenditure for the six months ended in Jun. 2023 was A$-0.00 Mil. Its Operating Income for the six months ended in Jun. 2023 was A$-1.44 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.

LTR Pharma Capex-to-Operating-Income Historical Data

The historical data trend for LTR Pharma's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LTR Pharma Capex-to-Operating-Income Chart

LTR Pharma Annual Data
Trend Jun21 Jun22 Jun23
Capex-to-Operating-Income
- - -

LTR Pharma Semi-Annual Data
Jun21 Jun22 Jun23
Capex-to-Operating-Income - - -

Competitive Comparison of LTR Pharma's Capex-to-Operating-Income

For the Biotechnology subindustry, LTR Pharma's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LTR Pharma's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LTR Pharma's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where LTR Pharma's Capex-to-Operating-Income falls into.


LTR Pharma Capex-to-Operating-Income Calculation

LTR Pharma's Capex-to-Operating-Income for the fiscal year that ended in Jun. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.002) / -1.436
=N/A

LTR Pharma's Capex-to-Operating-Income for the quarter that ended in Jun. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.002) / -1.436
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LTR Pharma  (ASX:LTP) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

LTR Pharma Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of LTR Pharma's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

LTR Pharma (ASX:LTP) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » Capex-to-Operating-Income
Comparable Companies
Traded in Other Exchanges
N/A
Address
9A/204 Alice Street, Brisbane, QLD, AUS, 4000
Website
https://www.ltrpharma.com
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on market.

LTR Pharma (ASX:LTP) Headlines

No Headlines